Alamar Biosciences, Inc.

Alamar Biosciences announced that its NULISA platform will be featured in over 140 poster and session presentations at the Alzheimer's Association International Conference (AAIC) from July 12-15. This significant increase in presentations, over four times the previous AAIC, highlights the widespread adoption of NULISA and ARGO HT technology in Alzheimer's research. Alamar will also host a workshop to showcase new data on its eMTBR-Tau and BD-pTau217 assays, demonstrating improved detection and staging of Alzheimer's disease.

Alamar Biosciences, Inc. announced the launch of its first commercial eMTBR-Tau immunoassay, a significant development for Alzheimer's disease research and diagnosis. This new assay, available in NULISAseq™ Neuro 220 multiplexed panel kits and as a single-plex assay, measures a plasma biomarker that specifically reflects tau tangle pathology, a core component of Alzheimer's progression. The NULISA platform enables highly sensitive and specific measurement, offering a non-invasive, blood-based alternative to traditional tau PET imaging. The company will present data on the assay's performance and clinical findings at the Alzheimer’s Association International Conference (AAIC) 2026.

Alamar Biosciences, Inc. completed its Initial Public Offering (IPO) on April 20, 2026, generating $197.8 million in net proceeds, following a one-for-2.418 reverse stock split on April 10, 2026. For the first quarter of 2026, the company reported a significant 98.8% increase in total revenue to $26.0 million, driven by strong product sales. However, the net loss for the quarter also widened to $21.3 million, reflecting increased operating expenses and a loss on remeasurement of convertible notes.

Alamar Biosciences reported strong financial results for Q1 2026, with total revenue nearly doubling to $26.0 million, a 99% increase year-over-year. The company also launched two new products in neurodegenerative disease research. Following the quarter end, Alamar Biosciences completed its initial public offering in April 2026, raising $197.8 million in net proceeds, significantly strengthening its balance sheet. Despite revenue growth, the company reported an increased net loss of $21.3 million, partly due to a loss on remeasurement of convertible notes.

Alamar Biosciences, Inc. announced the completion of its initial public offering on April 20, 2026, successfully raising approximately $219.9 million in gross proceeds. The company issued a total of 12,937,500 shares of common stock, including the full exercise of the underwriters' option, at a public offering price of $17.00 per share. Concurrently with the IPO closing, the company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, which were previously approved by its board and stockholders.